Actively Recruiting
Study of Oral CGT4255, a Selective ERBB2 Inhibitor, for Adults with Advanced Solid Tumors Showing ERBB2 or HER2 Alterations
Led by Cogent Biosciences, Inc. · Updated on 2026-02-27
100
Participants Needed
6
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating CGT4255, a selective ERBB2 inhibitor, in adults with advanced solid tumors that have ERBB2 genetic alterations or HER2 overexpression. This open-label, phase 11b study aims to assess the safety, tolerability, how the body processes the drug, how the drug affects the body, and its antitumor activity in these patients. The study is sponsored by Cogent Biosciences, Inc.
CONDITIONS
Brief Title
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Research Team
C
Cogent Biosciences, Inc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
